Alkem Lab


Getz Bros
Concise Prescribing Info
Cefuroxime (tab/powd for oral susp: axetil; inj: Na)
Mild to moderate infections including pharyngitis/tonsillitis; acute bacterial otitis media, maxillary sinusitis, & exacerbations of chronic bronchitis & secondary bacterial infections of acute bronchitis; uncomplicated skin & skin-structure infections, UTI, gonorrhea (urethral & endocervical); early Lyme disease (erythema migrans). Susp/Inj: Meningitis, peritonitis. Surgical infection prophylaxis. Inj: Infections including resp tract (infected bronchiectasis, bacterial pneumonia, lung abscess & post-op chest infections), UTI (acute & chronic pyelonephritis, cystitis & asymptomatic bacteriuria), soft tissue (cellulitis, erysipelas & wound infections), bone & joint (osteomyelitis & septic arthritis), obstet & gynaecological (pelvic inflammatory disease) infections; septicemia. Post splenectomy sepsis of unclear etiology.
Dosage/Direction for Use
Tab Adult & adolescent ≥13 yr Pharyngitis, tonsillitis & acute bacterial maxillary sinusitis 250 mg bid for 10 days. Acute bacterial exacerbations of chronic bronchitis & uncomplicated skin & skin-structure infections 250 or 500 mg bid for 10 days. Secondary bacterial infections of acute bronchitis 250 or 500 mg bid for 5-10 days. Uncomplicated UTI 250 mg bid for 7-10 days. Uncomplicated gonorrhea 1,000 mg once as single dose. Early Lyme disease 500 mg bid for 20 days. Childn Acute otitis media & acute bacterial maxillary sinusitis 250 mg bid for 10 days. Susp Adult 250 mg bid. Mild to moderate lower resp tract infections eg, bronchitis 250 mg bid. Severe lower resp tract infections or suspected pneumonia 500 mg bid. UTI 125 mg bid. Pyelonephritis 250 mg bid. Uncomplicated gonorrhea 1 g as single dose. Lyme disease Adult & childn >12 yr 500 mg bid for 20 days. Childn 125 mg bid or 10 mg/kg bid. Max: 250 mg daily. Otitis media Childn >2 yr 250 mg bid or 15 mg/kg bid. Max: 500 mg daily. Childn <2 yr 125 mg bid or 10 mg/kg bid. Max: 250 mg daily. IV/IM inj Adult 750 mg tid. Severe infections 1.5 g IV tid. Total daily dose: 3-6 g divided 6 hrly. Infant & childn 30-100 mg/kg/day in 3-4 divided doses. Neonate 30-100 mg/kg/day in 2-3 divided doses. Gonorrhea 1.5 g as single dose, given as two 750 mg inj into different sites eg, each buttock. Meningitis Adult 3 g IV every 8 hr. Infant & childn 200-240 mg/kg/day IV in 3-4 divided doses, may be reduced to 100 mg/kg/day after 3 days. Neonate Initially 100 mg/kg/day IV, may be reduced to 50 mg/kg/day after 3 days. Surgical prophylaxis 1.5 g IV w/ anesth induction. Abdominal, pelvic & orthopedic operations May be followed w/ two 750 mg doses 8 & 16 hr later. Vascular, cardiac, esophageal & pulmonary operations May be supplemented w/ 750 mg IM tid for a further 24-48 hr. Marked renal impairment (CrCl 10-20 mL/min), continuous peritoneal dialysis, renal failure on continuous arteriovenous hemodialysis or high-flux hemofiltration in intensive therapy units 750 mg bid. Severe renal impairment (CrCl <10 mL/min) 750 mg once daily. A further 750 mg should be given at the end of each dialysis session in patients on hemodialysis.
FC tab: May be taken with or without food. Powd for oral susp: Should be taken with food.
Hypersensitivity to cefuroxime or cephalosporins.
Special Precautions
Hypersensitivity to penicillins or other drugs. Penicillin-sensitive patients. Concomitant use w/ potent diuretics & aminoglycosides. History of colitis; fall in prothrombin activity in patients w/ renal or hepatic impairment, poor nutritional state, receiving a protracted course of antimicrobial therapy & previously stabilized on anticoagulant therapy. False -ve result in ferricyanide test; +ve Coombs' test. Pregnancy & lactation. Susp: Overgrowth of nonsusceptible organisms (eg, Enterococci & C. difficile) w/ prolonged use. Consider diagnosis of pseudomembranous colitis in patients who develop serious diarrhea. Phenylketonuria.
Adverse Reactions
Hypersensitivity reactions eg, anaphylaxis, angioedema, pruritus, rash, serum sickness-like reaction, urticaria. Pseudomembranous colitis; hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia, increased prothrombin time; hepatitis, cholestasis, jaundice; (transient elevation of liver enzymes;) seizure; erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis; renal dysfunction. Susp: Candida overgrowth, eosinophilia, headache, dizziness, GI disturbances including diarrhea, nausea, abdominal pain. Inj: Interstitial nephritis, drug fever; decreased in Hb conc, neutropenia; transient rises in liver enzymes or serum bilirubin; transient pain (IM); thrombophlebitis & burning sensation (IV); mild to moderate hearing loss in childn.
Drug Interactions
Prolonged excretion & elevated peak serum level w/ probenecid. May adversely affect renal function w/ potent diuretics or aminoglycosides. Lower oestrogen reabsorption & reduced efficacy of combined OCs. Reduced serum levels by dialysis.
MIMS Class
ATC Classification
J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Zocef powd for inj 750 mg
1's (P250/box)
Zocef powd for oral susp 125 mg/5 mL
30 mL x 1's (P187.5/box)
Zocef FC tab 250 mg
10's (P250/box);50's
Zocef FC tab 500 mg
10's (P450/box);50's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in